NCT03709121View on ClinicalTrials.gov

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

March 20, 2019

Study Completion Date

March 20, 2019

Conditions
Conjunctivitis, Allergic
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) dosed twice.

DRUG

Reproxalap Ophthalmic Solution (0.5%)

Reproxalap Ophthalmic Solution (0.5%) dosed twice.

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution dosed twice.

Trial Locations (1)

L4W 1V7/L4W 1N2

Inflamax Research Limited, Mississauga

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY